ProQR Therapeutics NV (PRQR)
3.67
+0.04
(+1.10%)
USD |
NASDAQ |
Nov 05, 10:36
ProQR Therapeutics Debt to Equity Ratio: 0.1351 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.1351 |
| March 31, 2024 | 0.1254 |
| December 31, 2023 | 0.1037 |
| September 30, 2023 | 0.113 |
| June 30, 2023 | 0.1254 |
| March 31, 2023 | 0.1098 |
| December 31, 2022 | 0.101 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.1026 |
| June 30, 2022 | 0.515 |
| March 31, 2022 | 0.4439 |
| December 31, 2021 | 0.3873 |
| September 30, 2021 | 0.1501 |
| June 30, 2021 | 0.1569 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.101
Minimum
Dec 2022
0.515
Maximum
Jun 2022
0.1976
Average
0.1254
Median
Jun 2023
Debt to Equity Ratio Benchmarks
| uniQure NV | 1.056 |
| Merus NV | 0.00 |
| argenx SE | -- |
| Pharming Group | 0.4226 |
| Pharvaris NV | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 126.54M |
| Total Liabilities (Quarterly) | 91.32M |
| Shareholders Equity (Quarterly) | 35.22M |
| Current Ratio | 2.730 |
| Net Debt Paydown Yield | 0.34% |